The Pharma Partnering US Summit 2023 is an exclusive and one of the most prestigious life sciences deal making International Conference coming to Bostion MA during 19th & 20th Oct 2023.
This platform brings together Senior Executives and Professionals from different parts of the world,
focused on Business Development & Licensing, R&D Collaborations, Commercialisation & Distribution Deals,
Fundraising, Investments, Alliances, M&A, Going Public as well as partnering Opportunities in the Broader Aspects.
Boston has a highly developed infrastructure for the biotech industry. The city is home to many specialized facilities, such as the Massachusetts Biotechnology Council, the Biogen Idec Innovation Center, and the Novartis Institutes for BioMedical Research.
Finally, Boston has a supportive regulatory environment that encourages innovation and growth in the biotech industry. The state of Massachusetts has implemented several initiatives to promote the life sciences sector, including tax incentives, grants, and loans for biotech companies.
The Pharma Partnering Summit brings together dealmakers of leading life science companies to put together a whole range of partnering opportunities. The Summit provides a prime Opportunity for You to meet & Network with Senior Executives of:
Business Development / Licensing / M&A / Strategic Alliances / External Innovation / Search & Evaluation / Legal & IP / Due Diligence / Scientific Assessments / Portfolie & Life cycle management / Venture Capital / Investments / Clinical Operations /Regulatory Affairs / Compliances / Commercialisation & Disturibution / Strategic R&D
And Many More from Big, Midsize and Small Pharma and Biotech Companies.
Dimitri has over 30 years’ experience in the pharmaceutical and biotech industry. He is a
and former CEO of ImmuPharma plc, a drug development biotech company listed on AIM of the
Stock Exchange and previously on Euronext in Brussels. His past roles include Senior
Worldwide Business Development at GlaxoSmithKline, where he was responsible for worldwide
transactions with a focus on licensing of IP rights for development and commercialization.
He held a
similar role at Bristol-Myers Squibb. Prior to that, he spent 8 years at Procter &
Gamble in its
pharmaceutical division, in senior marketing, R&D and business development positions and
career in marketing at Novartis in 1987. Over the last 20 years, he is also the founder and
Director of DyoDelta Biosciences, an advisory company specializing in providing support in
together corporate collaborations in the Life Sciences.
In the role of CEO, Joe Boncore manages MassBio’s federal affairs, state and municipal government relations,
and takes the lead on initiatives to sustain Massachusetts’ economic competitiveness focusing on issues around infrastructure,
workforce, and digital health. Prior to joining MassBio in September 2021,
Joe served as a Massachusetts State Senator for the First Suffolk and Middlesex districts, representing his hometown of Winthrop;
the Boston communities of East Boston, North End, Chinatown, Beacon Hill, Bay Village, and South End;
the Cambridge neighborhoods of Cambridgeport, Riverside and MIT; and the City of Revere.
While in the State Senate, Joe was the Chair of the Joint Committee on Transportation,
Chair of the Senate’s Committee on Personnel and Administration, Chair of the Joint Committee on Housing, and Vice Chair of Rules.
Before being elected to the state legislature in 2016,
Joe practiced law specializing in criminal law in his private practice and as a public defender with Suffolk Lawyers for Justice.
Sandra von Meier as Head of Business Development and Licensing at Debiopharm, Sandra is
responsible for all business development and licensing activities at Debiopharm, covering both
in licensing and out licensing activities, including all transactions.
Before joining Debiopharm, Sandra was working as Senior Director Business Development &
Licensing at Bayer responsible for oncology asset search, evaluation and transaction including
the recent M&A with Vividion Therapeutics. Before Bayer, as Director Business Development
Oncology at Merck KGaA, Sandra led numerous transactions, including the strategic collaboration
for Xevinapant, including deals with F-star/bispecific antibodies, Vertex/DDR portfolio and
Pfizer for Bavencio/avelumab. Sandra started her career at Medigene, a publicly listed German
biotechnology company, where she also closed several transactions including the
commercialization agreement with Astellas for Eligard.
Sandra studied Biochemistry at the FU Berlin and then moved to London for her Diploma at the
Institute of Cancer Research. She holds a PhD from University College London.
Andrew Leger is a business development professional with a foundation in drug development of
rare neuromuscular and metabolic diseases. He has a 15+ year track record of orchestrating
high-impact results by leading cross-corporate collaborations both in science and corporate
development. Both his science and business careers have allowed him to immerse in and accumulate
understanding of unmet medical need experienced by patients with rare diseases. Throughout both,
he has found that collaboration is a very effective way of achieving transformative advancements
in medicine that make the lives of people with a rare disease better and more meaningful. Andrew
received a BA from Cornell University in molecular biology and a PhD from Tufts University
School of Medicine in biochemistry. Andrew was a scientist in rare diseases at former Genzyme,
now Sanofi, and has worked in BD roles at Sanofi, Novartis, Acceleron, and now Ferrer, where he
serves as Head of BD in the United States.
Dawn Bell, Pharm.D. is former start-up CEO, board director and current Top 10 Pharma Exec (NYSE:
NVS). Her expertise spans value creation, business development, portfolio composition,
indication selection/sequencing, go-to-market strategy, and reimbursement. She is currently
Global Development Head of Strategic Partnerships at Novartis.
Previously, Dr. Bell was VP Clinical Development and Medical Affairs and member of the Executive
Committee for Novartis Pharma Canada, a $600M USD business, responsible for new product
planning, clinical development, and medical affairs. She oversaw launch preparations for 8 new
medicines across 5 therapeutic areas and built the gene therapy team that launched Zolgensma and
Luxturna. Earlier, Dr. Bell led the global development, registration and launch of Entresto
Prior to Novartis, she was founding CEO of Cool-Bio, a pre-clinical stage biotech company. She
served as General Manager of Canyon Pharmaceuticals, a clinical-stage rare-disease company.
After several years in academia, she joined The Medicines Company, acquired by Novartis in 2020
Responsible for managing strategic external global alliances and providing support for Innovation
Center pre-deal activities through agreement execution for the Immunology TA at Janssen.
Prior to joining Janssen R&D, worked as alliance, project, and portfolio manager in the
Gastrointestinal (GI) Drug Discovery Unit, primarily launching and managing external academic
and industry alliances within the Immunology portfolio at Takeda Pharmaceuticals.
Adna was a scientist and preclinical research manager supporting IND enabling studies in
inflammatory diseases before transitioning into business development and product planning at
Aldeyra Therapeutics. She got her start in the pharmaceutical industry working as an analytical
research associate at Roche LLC in Palo Alto, California.
Eirini is the Evaluations Lead at the Bristol Myers Squibb External Innovation Group (Oncology),
responsible for the evaluation and the development of the clinical strategy of external
opportunities (early & late stage) in order to maximize the potential of each asset and ensure
registrational and commercial success. In addition, she directs the activities of a
multi-functional team that manages a broad portfolio of BMS clinical collaborations of Ph1-3
combination trials. Prior to her time at BMS, Eirini held positions of increasing responsibility
at Roche External Development and Oncology Clinical Development teams. She holds a PhD in tumor
immunology from the University of Edinburgh, UK and completed her postdoctoral training at
Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York.
Mark has over 20 years of experience in the pharmaceutical industry and is currently a member of
Boehringer Ingelheim’s Venture Fund focused on digital health investments. Prior to joining the
Fund, Mark was the Global Head of Contracts and Alliance Management, a team within Business
Development and licensing that was responsible for leading transactions and the alliance
management of collaborations with academic and biotechnology partners. Mark’s career has
afforded diverse roles in drug discovery, operations, CRO management, financial management, and
Uma Makhija Verma is Senior Director, Business Development at Biogen. While Uma is responsible
for digital health and data related partnerships and investments, she also supports Biogen’s
diligence and transactions efforts in pharma therapeutics.
Prior to Biogen, Uma held roles of increasing responsibility in business development at Otsuka
Pharmaceuticals across digital health and pharma therapeutics, and held stints across consulting
including IMS Health and Ernst and Young.
Uma enjoys conceptualizing and executing win-win collaborations at the intersection of science
and technology that ultimately bring innovative solutions in areas of high patient and clinical
unmet need. Notable transactions include Biogen’s co-development and commercial collaboration
with digital therapeutic leader MedRhythms in MS, and Otsuka’s co-development and commercial
collaboration with Click Therapeutics in depression.
Uma holds a Bachelor of Arts in Molecular Biology and Biochemistry from Hampshire College,
Amherst, MA and earned a post-graduate degree in business from the Indian School of Business,
Rachel Bright is Head of Alliance Management, Virology, at Gilead Sciences, where she leads a
team responsible for Gilead’s Virology Strategic Alliances. She has broad scientific and
business leadership experience in drug discovery and development, and over 20 years of
experience in alliance management, business development, program management and research. Prior
to this role Rachel held roles in Alliance Management and Business Development at GRAIL,
Corporate Development and Program Management at Geron Inc., and Research at Abbott Vascular.
Rachel holds a BSc from Haverford College, PA, and a PhD and Postdoc from Stanford University
School of Medicine in Molecular Pharmacology, and received the Certified Licensing Professional
Steve Pessagno is an employee of GSK, where he has worked in a variety of commercial, operations,
and business development roles in his 25 years at the company. Currently an Alliance Director in
GSK’s Worldwide Business Development group, Steve manages a portfolio of strategic alliances
(primarily in Oncology), oversees the team’s priority projects for Alliance Management
operations, and has held leadership roles on several transformative acquisition and divestment
deals (examples include GSK’s acquisitions of Reliant Pharmaceuticals, Stiefel Laboratories, and
Tesaro; ViiV Healthcare’s acquisition of the HIV business from Bristol Myers Squibb; and the
divestment of GSK’s portfolio of marketed Oncology products to Novartis in 2015). Steve holds
degrees from the University of Pennsylvania (BA, Communications) and University of Michigan
(MBA), and serves on the Board of Directors (Treasurer, Ex-Officio) of the Coalition Against
Childhood Cancer (CAC2.org).
Christian Thomsen, Global Head of CNS BD&L at Boehringer-Ingelheim is responsible for bringing in
new opportunities and establishing collaborations supporting and expanding the BI pipeline
neuropsychiatry. Christian earned his PhD in neuropharmacology and has >25 years experience in
neuroscience drug discovery from Novo Nordisk and Lundbeck before joining Boehringer-Ingelheim
in Jan. 2019 LinkedIn: https://www.linkedin.com/in/christian-thomsen-21a5008/
Deborah Garrard is committed to advancing therapies to improve the lives of cancer patients by
leveraging the expertise and breaking down barriers across organizations. She has over 20 years
of experience in the biopharma industry working in Alliance Management, Product Leadership, and
Clinical Supply Operations. She has a BS in Molecular and Cellular Biology and an Executive MBA,
both from the University of Washington.
Jukka Muhonen has over twenty (20) years of experience in deal-making in the Pharma and Biotech
industries. During his tenure at Orion Corporation (Espoo, Finland) he has led organizations
ranging from Legal Affairs and IPR to Alliance Management and Global Business Development.
Through his varied global practice he has developed deep knowledge in creating value via
different deal structures and in the management of strategic alliances. He has been responsible
for numerous successful licensing and partnering deals, including a number of high-interest
licensing deals with Big Pharma companies as counter-parts. His core expertise lies in
transactions and M&A, commercial contracts, complex commercial negotiations and in building,
managing and restructuring contractual relationships. Since 2012 he is also a CEDR accredited
Monique joined Moderna in 2019 and is currently Senior Director of Program & Alliance Management
overseeing strategic alliances with corporate and academic collaborators in cardiovascular and
rare diseases. Prior to Moderna, Monique spent 19 years at Boston Children’s Hospital in the
Technology Innovation and Development Office (TIDO) supporting the translation of research and
clinical innovations into new products to benefit children and the greater public. At BCH, she
developed expertise in intellectual property evaluation and management, contract negotiation,
business development and alliance management. Working with researchers and clinicians, she
launched the BCH Technology Development Fund, an academic catalyst fund dedicated to de-risking
high-impact academic technologies to create a pipeline of investable technologies. To date, The
Technology Development Fund has led to the launch of several startups including Affinivax,
Rebion and Miach Orthopaedics. Monique holds a PhD in Biochemistry from the Tufts Graduate
School of Biomedical Sciences and trained as post-doctoral fellow in cancer biology at Harvard
Senior Director Search & Evaluation
Senior Director External Innovation DPDS
Executive Director Global Business Development
Director BD Oncology
Sr Director Global Partnering Neurosciences & Rare Diseases
Senior Director Business Development
Global Head of Research and Technology Search and Evaluation, Global Business Development
Sr Director, Global Partnering, Oncology
Business development director, Orion Corporation
An opportunity to interact, discuss and listen to the experts from
the industry and enhance your
knowledge and skills necessary to help you achieve your goals.
The agenda is structured for the needs of Pharma & Biotech Senior Executives. The US
2023 aims to help companies to expand their network by meeting Targeted Audience from all the continents, and put together deals to develop
The Summit also serves to provide insight on new paradigms for external innovations & disseminate knowledge through expert speakers, for
practices in the field of industry partnerships.
Identify suitable partners according to your
company’s needs, engage through one-to-one
meetings / networking sessions and develop your
Investment Opportunities with high returns for investor
as well as fundraising opportunities for life
science companies to expedite your innovations and reach
Exhibitions to promote your brands, products, services,
solutions, platforms and to develop your
Meet the right decision makers and achieve your business goals through pre-arranged
one-to-one meetings. All attendees will be provided with access to our meeting
platform which allows to search and identify potential partners, review information
about their business and manage all meeting requests in one dashboard.
16+ Hours of Networking:
Each day of summit you will have dedicated sessions for meetings and socialising.
This allows each attendee to enjoy over 16+ hours of networking opportunity to
engage with qualified leads.
Three weeks in advance, you will receive a secure login to our meeting platform,
through which you
will be able to send and receive meeting requests to and from partners of your
choice so that you
can enjoy well organised and pre-arranged meetings during the networking session.